IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). Jones JL, Phuah C-L, Cox AL, Thompson SA, Ban M, Shawcross J, Walton A, Sawcer SJ, Compston A, Coles AJ J Clin Invest. 2009 Jul; 119(7):2052-61. Epub 2009 Jun 22. PMID: 19546505. Abstract CommentRecommendBookmarkWatch